Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DAVID S HALLEGUA

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1063416964
CMS profile
183722
Location
BEVERLY HILLS, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$3,414.55

135 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $3,315.55 134
Education $99.00 1

By paying entity

PY2023 · entire year · sorted by reported total

Page 3 of 3; records 101–135 of 135 matching records. This page contains 35 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DAVID S HALLEGUA

NPI 1063416964 · CMS profile ID 183722

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

BEVERLY HILLS, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–135 of 135 matching records. This page contains 35 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1063416964?year=2023&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DAVID S HALLEGUA, NPI 1063416964, CMS profile ID 183722. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–135 of 135 matching records. This page contains 35 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1063416964?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). DAVID S HALLEGUA, NPI 1063416964, CMS profile ID 183722. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–135 of 135 matching records. This page contains 35 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1063416964?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
DAVID S HALLEGUA, NPI 1063416964, CMS profile ID 183722, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–135 of 135 matching records. This page contains 35 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1063416964?year=2023&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

135 matching records · $3,414.55 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 135 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–135 of 135.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $19.8803/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992269731 CMS
Amgen Inc. $32.9203/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019888807 CMS
Aurinia Pharma U.S., Inc. $19.8203/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057734637 CMS
Amgen Inc. $21.9403/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019888781 CMS
GlaxoSmithKline, LLC. $19.4403/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001295323 CMS
NESTLE HEALTHCARE NUTRITION INC. $16.6703/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012455373 CMS
Amgen Inc. $34.6003/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019888805 CMS
Novartis Pharmaceuticals Corporation $24.8603/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992269727 CMS
Amgen Inc. $34.0303/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019888765 CMS
Radius Health, Inc. $29.6103/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1024689023 CMS
Amgen Inc. $30.8803/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019888777 CMS
Janssen Biotech, Inc. $24.4502/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988019707 CMS
ABBVIE INC. $29.4002/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997422069 CMS
Lilly USA, LLC $33.2302/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031376301 CMS
Aurinia Pharma U.S., Inc. $23.4602/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057734635 CMS
Novartis Pharmaceuticals Corporation $19.9602/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992269723 CMS
AstraZeneca Pharmaceuticals LP $9.6302/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016099559 CMS
GlaxoSmithKline, LLC. $17.1002/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001295229 CMS
Amgen Inc. $27.2002/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019888763 CMS
Amgen Inc. $34.8102/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019888819 CMS
Novartis Pharmaceuticals Corporation $27.0102/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992269719 CMS
Exact Sciences Corporation $19.7102/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026644347 CMS
ABBVIE INC. $27.0901/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997422067 CMS
Amgen Inc. $19.5801/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019888793 CMS
GlaxoSmithKline, LLC. $17.7801/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001295205 CMS
Amgen Inc. $9.6701/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019888779 CMS
Aurinia Pharma U.S., Inc. $19.5301/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057734633 CMS
Radius Health, Inc. $33.7501/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1024689029 CMS
Novartis Pharmaceuticals Corporation $19.1701/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992269711 CMS
NESTLE HEALTHCARE NUTRITION INC. $16.5301/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012509419 CMS
AstraZeneca Pharmaceuticals LP $20.5901/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015096563 CMS
Amgen Inc. $28.8801/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019888799 CMS
Amgen Inc. $21.3101/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019888797 CMS
Amgen Inc. $33.2001/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019888795 CMS
Novartis Pharmaceuticals Corporation $22.3801/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992269707 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,435.63 170
PY2020 $1,890.38 88
PY2021 $2,847.46 144
PY2022 $3,716.44 169
PY2023 $3,414.55 135
PY2024 $3,143.98 127
PY2025 $3,680.25 146

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $117,077.77 53
PY2024 Principal investigator $102,450.50 10
PY2023 Principal investigator $36,491.82 9
PY2022 Principal investigator $6,798.92 1
PY2021 Principal investigator $6,798.92 1
PY2020 Principal investigator $9,187.12 3
PY2019 Principal investigator $65,053.19 9

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

53 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $6,456.00 12/04/2025 Non-covered Recipient Entity
DAVID S HALLEGUA MD A PROF CORP
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202527606
Principal investigator 1 ABBVIE INC. $29,024.40 11/04/2025 Non-covered Recipient Entity
DAVID S HALLEGUA MD A PROF CORP
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202520567
Principal investigator 1 ABBVIE INC. $10,903.00 10/09/2025 Non-covered Recipient Entity
DAVID S HALLEGUA MD A PROF CORP
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202514717
Principal investigator 1 ABBVIE INC. $20.66 08/07/2025 Non-covered Recipient Entity
DAVID S HALLEGUA MD A PROF CORP
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202503751
Principal investigator 1 ABBVIE INC. $23.10 08/07/2025 Non-covered Recipient Entity
DAVID S HALLEGUA MD A PROF CORP
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202503753
Principal investigator 1 ABBVIE INC. $20.60 08/05/2025 Non-covered Recipient Entity
DAVID S HALLEGUA MD A PROF CORP
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202501376
Principal investigator 1 ABBVIE INC. $28.54 07/31/2025 Non-covered Recipient Entity
DAVID S HALLEGUA MD A PROF CORP
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202500650
Principal investigator 1 ABBVIE INC. $1,266.44 07/31/2025 Non-covered Recipient Entity
DAVID S HALLEGUA MD A PROF CORP
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202500666
Principal investigator 1 ABBVIE INC. $13.11 07/31/2025 Non-covered Recipient Entity
DAVID S HALLEGUA MD A PROF CORP
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202500668
Principal investigator 1 ABBVIE INC. $41.84 07/31/2025 Non-covered Recipient Entity
DAVID S HALLEGUA MD A PROF CORP
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202500678
Principal investigator 1 ABBVIE INC. $394.97 07/31/2025 Non-covered Recipient Entity
DAVID S HALLEGUA MD A PROF CORP
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202500680
Principal investigator 1 ABBVIE INC. $45.65 07/31/2025 Non-covered Recipient Entity
DAVID S HALLEGUA MD A PROF CORP
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202500704
Principal investigator 1 ABBVIE INC. $14.30 07/29/2025 Non-covered Recipient Entity
DAVID S HALLEGUA MD A PROF CORP
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202500334
Principal investigator 1 ABBVIE INC. $16.36 07/29/2025 Non-covered Recipient Entity
DAVID S HALLEGUA MD A PROF CORP
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202500336
Principal investigator 1 ABBVIE INC. $54.74 07/29/2025 Non-covered Recipient Entity
DAVID S HALLEGUA MD A PROF CORP
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202500338
Principal investigator 1 ABBVIE INC. $17.78 07/29/2025 Non-covered Recipient Entity
DAVID S HALLEGUA MD A PROF CORP
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202500352
Principal investigator 1 ABBVIE INC. $25.16 07/29/2025 Non-covered Recipient Entity
DAVID S HALLEGUA MD A PROF CORP
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202500356
Principal investigator 1 ABBVIE INC. $82.01 07/24/2025 Non-covered Recipient Entity
DAVID S HALLEGUA MD A PROF CORP
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202499576
Principal investigator 1 ABBVIE INC. $58.92 07/24/2025 Non-covered Recipient Entity
DAVID S HALLEGUA MD A PROF CORP
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202499588
Principal investigator 1 ABBVIE INC. $191.88 07/21/2025 Non-covered Recipient Entity
DAVID S HALLEGUA MD A PROF CORP
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202499046
Principal investigator 1 ABBVIE INC. $138.02 07/17/2025 Non-covered Recipient Entity
DAVID S HALLEGUA MD A PROF CORP
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202498620
Principal investigator 1 ABBVIE INC. $144.72 07/17/2025 Non-covered Recipient Entity
DAVID S HALLEGUA MD A PROF CORP
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202498622
Principal investigator 1 ABBVIE INC. $150.97 07/17/2025 Non-covered Recipient Entity
DAVID S HALLEGUA MD A PROF CORP
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202498624
Principal investigator 1 ABBVIE INC. $43.28 07/17/2025 Non-covered Recipient Entity
DAVID S HALLEGUA MD A PROF CORP
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202498626
Principal investigator 1 ABBVIE INC. $91.68 07/17/2025 Non-covered Recipient Entity
DAVID S HALLEGUA MD A PROF CORP
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202498628
Principal investigator 1 ABBVIE INC. $230.06 07/17/2025 Non-covered Recipient Entity
DAVID S HALLEGUA MD A PROF CORP
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202498630
Principal investigator 1 ABBVIE INC. $138.02 07/17/2025 Non-covered Recipient Entity
DAVID S HALLEGUA MD A PROF CORP
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202498632
Principal investigator 1 ABBVIE INC. $28.54 07/17/2025 Non-covered Recipient Entity
DAVID S HALLEGUA MD A PROF CORP
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202498634
Principal investigator 1 ABBVIE INC. $20.00 07/17/2025 Non-covered Recipient Entity
DAVID S HALLEGUA MD A PROF CORP
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202498636
Principal investigator 1 ABBVIE INC. $80.47 07/17/2025 Non-covered Recipient Entity
DAVID S HALLEGUA MD A PROF CORP
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202498638
Principal investigator 1 ABBVIE INC. $296.90 07/17/2025 Non-covered Recipient Entity
DAVID S HALLEGUA MD A PROF CORP
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202498642
Principal investigator 1 ABBVIE INC. $33.25 07/17/2025 Non-covered Recipient Entity
DAVID S HALLEGUA MD A PROF CORP
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202498644
Principal investigator 1 ABBVIE INC. $103.14 07/17/2025 Non-covered Recipient Entity
DAVID S HALLEGUA MD A PROF CORP
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202498646
Principal investigator 1 ABBVIE INC. $343.88 07/17/2025 Non-covered Recipient Entity
DAVID S HALLEGUA MD A PROF CORP
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202498648
Principal investigator 1 ABBVIE INC. $28.54 07/17/2025 Non-covered Recipient Entity
DAVID S HALLEGUA MD A PROF CORP
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202498656
Principal investigator 1 ABBVIE INC. $36.32 07/17/2025 Non-covered Recipient Entity
DAVID S HALLEGUA MD A PROF CORP
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202498658
Principal investigator 1 ABBVIE INC. $138.02 07/17/2025 Non-covered Recipient Entity
DAVID S HALLEGUA MD A PROF CORP
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202498670
Principal investigator 1 ABBVIE INC. $80.47 07/17/2025 Non-covered Recipient Entity
DAVID S HALLEGUA MD A PROF CORP
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202498672
Principal investigator 1 ABBVIE INC. $28.54 07/17/2025 Non-covered Recipient Entity
DAVID S HALLEGUA MD A PROF CORP
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202498674
Principal investigator 1 ABBVIE INC. $44.58 07/17/2025 Non-covered Recipient Entity
DAVID S HALLEGUA MD A PROF CORP
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202498686
Principal investigator 1 ABBVIE INC. $138.02 07/17/2025 Non-covered Recipient Entity
DAVID S HALLEGUA MD A PROF CORP
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202498688
Principal investigator 1 ABBVIE INC. $156.73 07/17/2025 Non-covered Recipient Entity
DAVID S HALLEGUA MD A PROF CORP
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202498690
Principal investigator 1 ABBVIE INC. $42.71 07/17/2025 Non-covered Recipient Entity
DAVID S HALLEGUA MD A PROF CORP
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202498692
Principal investigator 1 ABBVIE INC. $144.72 07/17/2025 Non-covered Recipient Entity
DAVID S HALLEGUA MD A PROF CORP
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202498694
Principal investigator 1 ABBVIE INC. $28,369.20 07/02/2025 Non-covered Recipient Entity
DAVID S HALLEGUA MD A PROF CORP
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202495213
Principal investigator 1 ABBVIE INC. $11,057.00 05/06/2025 Non-covered Recipient Entity
DAVID S HALLEGUA MD A PROF CORP
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202481737
Principal investigator 1 ABBVIE INC. $138.02 04/24/2025 Non-covered Recipient Entity
DAVID S HALLEGUA MD A PROF CORP
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202478804
Principal investigator 1 ABBVIE INC. $138.02 04/23/2025 Non-covered Recipient Entity
DAVID S HALLEGUA MD A PROF CORP
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202478514
Principal investigator 1 ABBVIE INC. $6,626.00 04/03/2025 Non-covered Recipient Entity
DAVID S HALLEGUA MD A PROF CORP
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202468853
Principal investigator 1 ABBVIE INC. $138.02 03/13/2025 Non-covered Recipient Entity
DAVID S HALLEGUA MD A PROF CORP
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202463469
Principal investigator 1 ABBVIE INC. $80.47 03/13/2025 Non-covered Recipient Entity
DAVID S HALLEGUA MD A PROF CORP
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202463473
Principal investigator 1 ABBVIE INC. $7,552.00 03/06/2025 Non-covered Recipient Entity
DAVID S HALLEGUA MD A PROF CORP
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202458087
Principal investigator 1 ABBVIE INC. $11,598.00 02/05/2025 Non-covered Recipient Entity
DAVID S HALLEGUA MD A PROF CORP
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202444374